Orexo AB (FRA:C5G)
€ 1.078 0.203 (23.2%) Market Cap: 37.46 Mil Enterprise Value: 78.99 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 53/100

Q4 2019 Orexo AB Earnings Call Transcript

Jan 30, 2020 / 01:00PM GMT
Release Date Price: €7.03 (+8.66%)
Operator

Hello, and welcome to the Orexo Interim Report Q4 2019. (Operator Instructions)

Today, I'm pleased to present Nikolaj Sørensen, Chief Executive Officer; and Joseph DeFeo, Chief Financial Officer. Please go ahead with your meeting.

Nikolaj SÃ;rensen;publ;President;CEO
Orexo AB

¸ - ()-&

Thank you very much, and welcome to this fourth quarter and full year result presentation for Orexo. It should probably not come to any surprise to you that in the morning when we were publishing our Q report, we were not really expecting the reaction that we've seen on the stock exchange today. So I have to be humble and consider what are those misconceptions that I would need to address during this call, and I hope I have identified a few of those. One of them is definitely around Zubsolv and our ability to grow Zubsolv on the mid- to long term. And let there be no doubt, we are pretty confident that Zubsolv will continue to be a very strong growth driver, both on our top line and our EBIT contribution.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot